BioLineRx Ltd.
BLRXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jun 17, 2025 |
| Jones Trading | upgrade | Hold →Buy | May 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 28, 2025 |
| Jones Trading | downgrade | Buy →Hold | Apr 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 29, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 29, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 31, 2023 |
| Oppenheimer | maintain | Outperform | May 25, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 23, 2021 |
| HC Wainwright & Co. | maintain | Buy | Dec 16, 2020 |
| Maxim Group | downgrade | Buy →Hold | Nov 25, 2020 |
| JMP Securities | maintain | Market Outperform →Outperform | Nov 25, 2020 |
| Oppenheimer | maintain | Outperform | Nov 25, 2020 |
| Maxim Group | upgrade | Hold →Buy | Nov 25, 2020 |
| Oppenheimer | maintain | Outperform | Aug 4, 2017 |
| Maxim Group | upgrade | Hold →Buy | May 18, 2017 |
| Rodman & Renshaw | maintain | Buy | Feb 13, 2017 |
Earnings History
Next report: Nov 23, 2026 · EPS est. $-0.39| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 31, 2026 | $-0.77 | $-0.15 | $294.0K | $500.0K |
| May 27, 2026 | $-0.58 | $-1.04 | $477.0K | $343.0K |
| Mar 23, 2026 | $-0.34 | $-0.50 | $194.0K | $514.0K |
| Nov 24, 2025 | $-0.22 | $-0.41 | $427.0K | $990.0K |
| Aug 14, 2025 | $-1.00 | $-0.35 | $304.0K | $661.3K |
| May 27, 2025 | $1.39 | $-0.84 | $255.0K | $1.5M |
| Mar 31, 2025 | $-1.60 | $-0.81 | $11.7M | $7.7M |
| Nov 25, 2024 | $-2.80 | $-0.05 | $4.9M | $5.3M |
News
GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of PARP inhibitors In an HR-proficient ovarian cancer patient-derived xenograft model, low-doses of GLIX1 plus olaparib demonstrated statistically significant tumor growth inhibition versus vehicle control, and tumor growth inhibition comparable to cisplatin TEL AVIV, Israel, and OSLO, No…
TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philade…
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent antitumor activity in TMZ-resistant patient-derived xenograft (PDX) GBM in vivo model - - Announced additional data demonstrating strong synergistic effect between GLIX1 and PARP inhibitor in patient-derived HR-proficient ovarian cancer xenograft model - - Management to host conference call today, August 3…
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per ADS (or per ADS equivalent) through a registered direct…
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd.